Skip to content
MarketNewsAPI
Product Live news Screener Coverage Pricing
Docs Overview REST API WebSocket API MCP server
Resources Use cases Blog Changelog Status Compare Contact
Log in Get API key Dashboard
PHRRF$0.04+0.00(+2.70%)PharmaTher Builds Portfolio of Personalized, 3D-Printed Peptide Products for New U.S. Peptide Pathway, Led by Colon-Targeted KPV and BPC-157[10:01:00 AM ET]ROK$446.65+2.83(+0.64%)Rockwell Automation Introduces SecureOT Capabilities to Help OEMs Address Emerging Cybersecurity Regulations Rockwell Automation, Inc. (NYSE: ROK), the world's largest company dedicated to industrial automation and digital transformation, today announced new ...[10:00:00 AM ET]APPN$51.01-0.95(-1.83%)Appian Announces 2026 US Public Sector Partner Award Winners Appian (Nasdaq: APPN) today announced the winners of its 2026 US Public Sector Partner Awards at Appian Government. The annual awards recognize...[10:00:00 AM ET]EDGM$0.00-0.00(-33.33%)EdgeMode Answers the Call for Ready-to-Build Data Center Infrastructure to Shorten Lead Times[10:00:00 AM ET]AUXXF$0.30+0.02(+6.05%)A2GOLD TO SELL BOLO FOR $1.5 MILLION AND UP TO $2.8M IN CONTINGENT PAYMENTS A2Gold Corp. ("A2Gold" or the "Company") (TSX-V: AUAU) (OTCQX: AUXXF) (FRA: RR7) is pleased to announce that it has entered into a definitive Mining...[9:41:00 AM ET]ZENA$0.92-0.00(-0.43%)AI Transforming Land Surveying as Billions in Geospatial and Construction Markets Fuel New Growth Opportunities[9:40:00 AM ET]SGU$13.06-0.02(-0.11%)Bally's Corporation Comments on The Star Entertainment Group AUSTRAC Decision and Continued Turnaround[9:39:00 AM ET]AIDX$0.25-0.00(-1.17%)20/20 BioLabs to Host November 4 Investor Webinar on OneTest™ Commercial Expansion and Growth Strategy[9:37:50 AM ET]NVAX$10.36+0.04(+0.39%)Novavax Earns $125 Million Milestone as Sanofi Launches Phase 3 Influenza-COVID-19 Combination Vaccine Trial in Europe Novavax (Nasdaq: NVAX) has earned a $125 million milestone payment with the initiation (fifth patient dosed) of Sanofi's Phase 3 influenza-COVID-19...[9:37:00 AM ET]APPN$51.01-0.95(-1.83%)Appian Marks Major Milestone in Supporting US Army Ammunition Modernization Appian (NASDAQ: APPN) today announced that the US Army fielded the initial release of the Total Army Combat and Training Munitions Information System ...[9:35:00 AM ET]DTE$133.38+1.42(+1.08%)DTE Energy and sonnen Launch Michigan's First Residential Battery Virtual Power Plant Pilot to Explore New Ways to Lower Energy Costs DTE Energy and sonnen today announced the launch of Michigan's first residential battery virtual power plant (VPP) pilot at Veridian at County Farm,...[9:34:00 AM ET]MAN$45.61-0.14(-0.31%)TAPFIN Marks Five Consecutive Years of Everest Group SOW PEAK Matrix® Leadership Talent Solutions TAPFIN, part of the ManpowerGroup (NYSE: MAN) family of brands, has been named a Global Leader and Star Performer in the Everest...[9:31:00 AM ET]KEY$21.48+0.28(+1.30%)KeyBank's Key Secured Credit Card(R) Program Surpasses 48,000 Client Graduations Since 2019[9:30:00 AM ET]

ARTL · NASDAQ

Artelo Biosciences, Inc.

$2.39 +0.01 (+0.42%)

Company overview

Artelo Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing treatments that modulate the endocannabinoid system. Its product candidate pipeline includes ART27.13, a synthetic G protein-coupled receptor agonist currently in a Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic CBD cocrystal for inflammatory bowel disease and post-traumatic stress disorder; and ART26.12, a fatty acid binding protein 5 inhibitor for prostate and breast cancer treatment, as well as for treating PTSD. The company has a research collaboration with Trinity College Dublin to investigate ART27.13 for cancer cachexia. Artelo Biosciences was formerly known as Reactive Medical, Inc. and changed its name to Artelo Biosciences, Inc. in April 2017.

Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Market cap
$8.3M
Employees
6
Headquarters
Solana Beach, CA
Website
artelobio.com
CEO
Gregory D. Gorgas
Listed
June 21, 2019
P/E
-0.26
Dividend yield
0.00%

Company financials

Revenue
$0.00
Gross profit
$0.00
Operating income
-$11.7M
EBITDA
-$12.8M
Net income
-$13.5M
EPS
-$9.23
Total assets
$12.5M
Total debt
$755,000
Earnings yield
-386.32%

Price chart

0.6510.1119.5729.0238.48
ARTL 1D NASDAQ O2.24H2.42L2.24C2.38+0.18 (+8.18%)Vol8.44K

News

15-min delaySigned-out view is delayed 15 minutes. Log in on Pro for the live news desk.

Start 7-day free trial See live plans
Source
Date
Type
Ticker Type Headline Source Published
ARTLArtelo Biosciences, Inc. Press release Artelo Biosciences to Present ART27.13 Data Demonstrating Potential to Treat Chemotherapy-Induced Neuropathic Pain at the IASP 2026 World Congress on Pain GlobeNewswire
ARTLArtelo Biosciences, Inc. Press release Artelo Biosciences to Showcase First-in-Human FABP5 Inhibitor ART26.12 as a Novel Approach to Pain Treatment at IASP 2026 World Congress on Pain GlobeNewswire
ARTLArtelo Biosciences, Inc. Stock news Artelo Biosciences, Inc. (NASDAQ:ARTL) Stock Short Interest Rises 104.7% Defense World
ARTLArtelo Biosciences, Inc. Press release Artelo Biosciences Selected for its First-Ever Company Presentation at BIO-Europe 2026 to Showcase Clinical Progress and Expanding Potential of its Novel FABP5 Inhibitor Platform GlobeNewsWire
ARTLArtelo Biosciences, Inc. Press release Artelo Biosciences Files New Provisional Patent Application GlobeNewswire
ARTLArtelo Biosciences, Inc. Press release Artelo Biosciences Announces ART27.13 Achieved Weight Loss GlobeNewswire
ARTLArtelo Biosciences, Inc. Press release Artelo Biosciences to Present at the H.C. Wainwright 28th Annual Global Investment Conference GlobeNewswire
ARTLArtelo Biosciences, Inc. Press release Artelo Biosciences Announces Reverse Stock Split GlobeNewsWire
ARTLArtelo Biosciences, Inc. Press release Artelo Biosciences Secures Notice of Allowance in Japan for Patent Claims for the Intended Commercial Formulation of ART27.13 GlobeNewsWire
ARTLArtelo Biosciences, Inc. Press release Artelo Biosciences Receives a Notice of Allowance from the U.S. Patent and Trademark Office for its Lead Investigational Drug Currently in Two Phase 2 Studies GlobeNewsWire
ARTLArtelo Biosciences, Inc. Press release Artelo Biosciences Provides Business Update and Reports 2026 Second Quarter Financial Results GlobeNewsWire
ARTLArtelo Biosciences, Inc. Press release Artelo Biosciences Announces Results from a Nonclinical Osteoarthritis Study Supporting ART26.12 as a Potential First-in-Class New Therapy for Chronic Pain Conditions GlobeNewsWire
ARTLArtelo Biosciences, Inc. Press release Artelo Biosciences Issues Reminder to Shareholders to Vote in Advance of Annual Meeting on July 17, 2026 GlobeNewsWire
ARTLArtelo Biosciences, Inc. Stock news Artelo Biosciences Announces Positive Results with ART27.13 in a Nonclinical Model of Paclitaxel-Induced Peripheral Neuropathy Globe News Wire
ARTLArtelo Biosciences, Inc. Press release Artelo Biosciences Announces Positive Results with ART27.13 in a Nonclinical Model of Paclitaxel-Induced Peripheral Neuropathy GlobeNewsWire
ARTLArtelo Biosciences, Inc. Press release Artelo Biosciences Announces New Data Supporting ART26.12 as a Potential First-in-Class Therapy for Chronic Pain associated with Spinal Cord Injury GlobeNewsWire
ARTLArtelo Biosciences, Inc. Press release Artelo Biosciences Presents ART26.12 Human Metabolite Data Demonstrating Favorable Drug Metabolism Characteristics Associated with Clinical Development Success GlobeNewsWire
DY Stock news Crude Oil Falls Over 5%; Dycom Industries Shares Surge Following Q1 Results Benzinga
ARTLArtelo Biosciences, Inc. Press release Artelo Biosciences Announces Strategic Collaboration with Artificial Intelligence (AI) Leader ScienceMachine Highlighting New Expansion Opportunities and Insights for FABP5 Inhibitor Development GlobeNewsWire
ARTLArtelo Biosciences, Inc. Press release Artelo Announces Peer-Reviewed Publication Supporting its FABP5 Inhibitor ART26.12 as a Novel Pain Treatment with a Potentially First-in-Class Profile GlobeNewsWire
See more
FAQ

Questions about Artelo Biosciences, Inc.

What does Artelo Biosciences, Inc. do?
Artelo Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing treatments that modulate the endocannabinoid system. Its product candidate pipeline includes ART27.13, a synthetic G protein-coupled receptor agonist currently in a Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic CBD cocrystal for inflammatory bowel disease and post-traumatic stress disorder; and ART26.12, a fatty acid binding protein 5 inhibitor for prostate and breast cancer treatment, as well as for treating PTSD. The company has a research collaboration with Trinity College Dublin to investigate ART27.13 for cancer cachexia. Artelo Biosciences was formerly known as Reactive Medical, Inc. and changed its name to Artelo Biosciences, Inc. in April 2017.
What is ARTL's market cap?
Artelo Biosciences, Inc. (ARTL) is a listed stock with a live quote. The latest market cap on this page is $8.3M.
Where is Artelo Biosciences, Inc. headquartered?
Artelo Biosciences, Inc. is headquartered in Solana Beach, CA.
How do I get ARTL news from the API?
Call GET /v1/news?tickers=ARTL. Add type=news, type=press_release, or type=legal to take one feed. Pro keys search the full archive in real time. Free keys are delayed 15 minutes and return the last year. Signed-out visitors and Free accounts see that same year on this page. Pro sees the full archive.
How far back does ARTL news go?
Signed-out visitors and Free accounts see the last year of stock news, press releases, and legal notices for ARTL, 15 minutes behind, and each headline links to the publisher. Pro, including the 7-day trial, sees the full archive as headlines are ingested. A Free API key returns the last year. Pro keys search the full archive.
Is the ARTL price on this page from the API?
The price and daily change update during the US session for every visitor. That quote is context on this page. It is not part of the news API. The chart is one candle per session from the start of 2020. 1W, 1M, and 1Y group those sessions.
Can I use the Pro plan commercially?
No. The Pro plan cannot be used for commercial work. A product you sell, work you do for a client, or redistribution of the feed needs a custom plan and a license. Email [email protected].

Real-time stock news for $15 a month.

Start a 7-day Pro trial. A card is required. REST, WebSocket, and MCP are included, with 1,000 REST requests a day. You won't be charged during the trial. Unless you cancel, the card is billed for Pro when it ends.

Start 7-day free trial Read the docs